II. Indications
-
Solid Organ Transplant
Immunosuppression (maintenance prevention of rejection)
- Cyclosporine (FDA approved)
-
Rheumatoid Arthritis
- Cyclosporine (FDA approved)
-
Psoriasis
- Cyclosporine (FDA approved)
- Autoimmune Conditions
- Thrombocytopenia (chronic, idiopathic, refractory)
- Psoriatuc Arthritis
III. Mechanism
- Calcineurin
- Serine-ThreonineProtein phosphatase that dephosphorylates phosphoproteins
- Histones
- Myosin light chain
- CAMP-dependent Protein kinases
- Calcineurin is composed of 2 subunits that are dependent on calmodulin and Calcium
- Calcineurin A (catalytic subunit, calmodulin-binding)
- Calcineurin B (regulatory subunit, Calcium sensitive)
- Calcineurin is key to immune function via the dephosphorylation of NFAT (nuclear factor)
- Promotes the transcription and synthesis of Cytokines (e.g. Interleukin 2) with T Cells (esp. T Helper Cells)
- Calcineurin also increases the number of Interleukin receptors on cytotoxic T Cells
- Calcineurin promotes the activation, proliferation, and differentiation of T Lymphcytes
- Calcineurin also increases Proteinuria in Glomerulonephritis (e.g. Lupus Nephritis)
- Calcineurin dephosphorylates synaptopodin, triggering further proteolysis to active metabolites
- Synaptopodin metabolites destabilize the glomerulus basement membrane podocytes
- Calcineurin also plays an important role in other signal transduction and pathway regulation
- Glycolysis
- Sperm Motility
- Nuclear translocation of NFATC1 transcription factor
- Dopaminergic signal transduction
- NMDA receptor-dependent synaptic plasticity
- Serine-ThreonineProtein phosphatase that dephosphorylates phosphoproteins
- Calcineurin Inhibitor (CNI)
- Inhibit the phosphatase activity of Calcineurin via immunophilin (cytoplasmic receptor) binding
- Voclosporin and Cyclosporine bind cyclophilin
- Pimecrolimus and Tacrolimus bind FK-binding Proteins
- CNIs are primarily used as Immunosuppressants in Solid Organ Transplant and Autoimmune Conditions
- CNIs inhibit T-Cell mediated Immunity via decreased Interleukin 2 related mechanisms (as above)
- Inhibit the phosphatase activity of Calcineurin via immunophilin (cytoplasmic receptor) binding
IV. Medications
- Cyclosporine (Sandimmune)
- Tacrolimus (Prograf)
- Voclosporin
-
Pimecrolimus
- Topical only (used in Atopic Eczema)
V. Adverse Effects
- Cardiovascular adverse effects
- Neurologic adverse effects
- Secondary Malignancy
- Squamous cell cancer
- Lymphoproliferative disorders
- Miscellaneous adverse effects
- Nephrotoxicity
- Hyperkalemia
- Gingival Hyperplasia (Cyclosporine)
- Diabetes Mellitus (Tacrolimus)
VI. Drug Interactions: Agents that increase Calcineurin Inhibitor concentrations
- See Cytochrome P-450 3A4
- Applies to Cyclosporine, Tacrolimus and Voclosporin
-
Antibiotics
- Aminoglycosides
- Ofloxacin (other Fluoroquinolones such as Ciprofloxacin and Levofloxacin may be used with caution)
- Erythromycin (and Clarithromycin to a lesser extent)
- Metronidazole (Flagyl)
-
Antifungal agents
- Amphoteracin B
- Fluconazole
- Itraconazole
- Ketoconazole
- Cardiovascular agents
- Amiodarone
- Spironolactone (Hyperkalemia risk)
- Nondihydropyridine Calcium Channel Blockers (Diltiazem, Verapamil)
- Foods
- Grapefruit (and juice)
- Pineapple, papaya (affect Cyclosporine)
- Pomegantes (and juice)
- Misellaneous agents
VII. Drug Interactions: Agents that decrease Calcineurin Inhbitor concentrations
- See Cytochrome P-450 3A4
- Applies to Cyclosporine, Tacrolimus and Voclosporin
- Antibiotics
- Seizure medications
- Supplements
- Echinacea (risk of Transplant Rejection)
- St. John's Wort
- Gastrointestinal agents
- Miscellaneous agents
VIII. Resources
- Calcineurin Inhibitors (Stat Pearls)